Session: MON 776-795-Cardiometabolic Risk & Vascular Biology
Poster Board MON-794
The authors studied the prevalence and treatment of HTA and dislipidemia in 115 DM2 patients, during their first 3 years of follow-up in an Endocrinology Center. One-way ANOVA or paired t-test were used to study normally distributed variables.
At baseline, DM2 duration was 7 years, glomerular filtration rate (GFR) was 93 ml/min and 87 patients had HTA with average systolic and diastolic values of 136/76 mmHg. Anti-hypertensive drugs were administered to 95% of patients with HTA ((ACE inhibitors 18%, ACE inhibitors plus Thiazide 8%, Angiotensin Receptor Antagonists (ARA) plus Thiazide 7%)).
Dislipidemia was present in 90 patients, with mean total cholesterol (Tc) of 190 mg/dL, LDL cholesterol (cLDL) of 112 mg/dL, HDL cholesterol (cHDL) of 50 mg/dL, triglicerides of 154 mg/dL and non-HDL Cholesterol of 139 mg/dL. Only 41% were under pharmacological treatment (47% with sinvastatin; 17% with atorvastatin 13% with rosuvastatin and 6% with sinvastatin plus ezetimibe).
At the end of 3 years, GFR was 97 ml/min (NS), 95 patients had HTA (p<0,01), with average systolic and diastolic values of 137/71 mmHg (NS). The number of patients treated with anti-hypertensive drugs increased to 96% (ACE inhibitors 19%, ACE inhibitors plus Thiazide 9%, ARA plus Thiazide 7%).
Also, there was an increase of dislipidemic patients to 94 (NS), with a decrease in TC to 174 mg/dL (p<0, 05) and non-HDL to 124 mg/dL (p<0,001). The number of treated dislipidemic patients increased to 70% (44% with sinvastatin; 20% with rosuvastatin, 9% with atorvastatin, and 7,5% with sinvastatin plus ezetimibe) (p<0,01).
Despite the increase in the number of hypertensive patients, blood pressure did not increase during the 3 year period. Regarding dislipidemia, there was an increase in the number of treated patients along with a decrease in TC and non-HDL over time, although recommend targets were not met.
Nothing to Disclose: TLN, BDP, HVL, AV, ACM, IM, MCC, LR, JP
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters